© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Lexeo Therapeutics, Inc. Common Stock (LXEO) shows an Average True Range (ATR) of 0.67 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 1.44M, indicating liquidity. These fundamental metrics provide insight into LXEO's underlying financial health and market activity.
Lexeo Therapeutics, Inc. Common Stock (LXEO) technical indicators as of December 23, 2025: the SMA 20 is 11.11%, SMA 50 at 14.65%, and SMA 200 at 95.2%. The RSI 14 value is 64.06, suggesting its current momentum. These technical analysis signals help assess LXEO's price trends and potential future movements.
Lexeo Therapeutics, Inc. Common Stock (LXEO) stock performance overview as of December 23, 2025: The 52-week high is $10.9 (currently -1.48% below), and the 52-week low is $1.45 (currently 633.1% above). Over the past year, LXEO's performance is 50.14%, compared to the S&P 500's 10.56% change.
According to market data, Lexeo Therapeutics, Inc. Common Stock (LXEO) stock's recent performance metrics show that over the last month, LXEO is 16.94%, with a Year-to-Date (YTD) performance of 61.55%. Over the past year, the stock has seen a 50.14% change. These figures summarize LXEO's price movements across various periods, reflecting its historical returns.
According to current financial data, LXEO stock's P/E (TTM) ratio is -4.01, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for LXEO, including P/S (394.78), P/B (3.31), and P/FCF (-8.06), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.